Aspira Women’s Health Announces Appointment of Dr. Sandra Milligan as Interim CEO
CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transition December 16, 2024 08:45 ET AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic…
Aspira Women’s Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award
The Company received the first $2 million from the ARPA-H Sprint for Women’s Health Award December 03, 2024 08:00 ET AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion…
Aspira Women’s Health Reports Selected Third Quarter 2024 Financial Results
November 14, 2024 08:00 ET Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30…
Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®
BioReference team is now able to provide the entire OvaSuite portfolio to healthcare providers in New York and New Jersey November 07, 2024 08:00 ET AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools,…
Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024
Management to Announce Earnings Results and hold a call at 8:30 am ET November 04, 2024 08:00 ET AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the…
Aspira Women’s Health Issues Letter to Shareholders and Announces Virtual Research & Development Day on October 29, 2024
Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company’s development pipeline October 25, 2024 08:00 ET AUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic…
Aspira Women’s Health Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis October 23, 2024 11:23 ET AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has…
Aspira Women’s Health Receives Approval from New York State Department of Health for OvaWatch®
New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State October 15, 2024 16:05 ET AUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease…
Aspira Women’s Health Announces Publication of Data Demonstrating Performance of its In-Development Blood Test for the Assessment of Malignancy Risk in Patients with an Adnexal Mass
The addition of miRNA and metadata to Aspira’s existing protein assay shows promising improvements in both sensitivity and specificity for early-stage ovarian cancer in women with an adnexal mass September 10, 2024 08:00 ET AUSTIN, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company…
Aspira Women’s Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 06, 2024 08:00 ET AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, CEO of Aspira Women’s Health will present at the H.C. Wainwright 26th Annual Global Investment…
Aspira Women’s Health Selected as a Spoke for the Investor Catalyst Hub
“Spoke” designation acknowledges Aspira’s position as an innovator in women’s health, and provides new opportunities for funding, thought leadership and networking with other healthcare industry leaders September 05, 2024 08:00 ET AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the…
Aspira Women’s Health Partners with Dorsata to Create New Clinical Workflow Tool for Adnexal Masses
The innovative new tool will be made available for integration into Electronic Medical Records at over 300 clinical sites serving 2,500 clinical users August 27, 2024 08:00 ET AUSTIN, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic…
Aspira Women’s Health Reports Second Quarter 2024 Financial Results
August 12, 2024 16:05 ET Q2 2024 OvaSuiteSM revenue of $2.4 million and volume of 6,471 units Q2 2024 cash utilization decreased by 16% compared to Q1 2024 Full year 2024 cash guidance decreased to $13-$14.5 million Conference Call and Webcast scheduled for today at 4:30 pm ET AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE)…
Aspira Women’s Health’s Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women’s Health (NPWH) Women’s Healthcare Conference
August 05, 2024 08:37 ET AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the 27th Annual National Association of Nurse Practitioner’s in Women’s Health (NPWH) Woman’s Healthcare…
Aspira Women’s Health Announces Poster Presentation at the Menopause Society’s 2024 Annual Meeting
Presentation to highlight data demonstrating OvaWatch’s performance in assessing ovarian cancer risk in pre- and post-menopausal women August 01, 2024 08:00 ET AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a…
Aspira Women’s Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12
July 31, 2024 16:05 ET AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30,…
Aspira Women’s Health Appoints Mr. John Ragard to its Board of Directors
Mr. Ragard further strengthens the Board bringing more than 46 years of significant public equity investment and Wall Street experience July 29, 2024 09:00 ET AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools,…
Aspira Women’s Health Announces Preliminary Second Quarter 2024 OvaSuite Product Volume and Highlights
Preliminary OvaWatch® volume during Q2 2024 grew 24% over the prior quarter to 1,307 units Preliminary OvaSuiteSM volume during Q2 2024 grew 11% over the prior quarter to 6,471 units AUSTIN, Texas, July 10, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused…
Aspira Women’s Health Announces Closing of $1.9 Million Private Placement Equity Financing
July 09, 2024 12:12 ET AUSTIN, Texas, July 09, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has closed its previously announced private placement for the issuance and sale of…
Aspira Women’s Health Announces $1.935 Million Private Placement Equity Financing
July 01, 2024 17:24 ET AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing…
Aspira Women’s Health Provides Commercial, Reimbursement and Cash Guidance Updates
June 13, 2024 08:00 ET Monthly OvaSuiteSM product volume grew by more than 26% in May compared to January Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite Cash used in operations guidance for 2024 expected to be lowered AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the…
Aspira Women’s Health to Present at the A.G.P. Healthcare Showcase on May 21
May 16, 2024 08:00 ET AUSTIN, Texas, May 16, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the Alliance Global Partner’s Healthcare Showcase taking…
Aspira Women’s Health Reports First Quarter 2024 Financial Results
May 15, 2024 07:30 ET Q1 2024 OvaSuiteSM revenue of $2.2 million and volume of 5,829 units Q1 2024 cash utilization of $4.4 million, a decrease of 22% compared to Q1 2023 Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc.…
Aspira Women’s Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15
May 08, 2024 08:47 ET AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31,…
Aspira Women’s Health Announces Publication of Two OvaWatch Peer-Reviewed Manuscripts
May 07, 2024 08:00 ET AUSTIN, Texas, May 07, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of two peer-reviewed manuscripts. The first manuscript, entitled “Ovarian Cancer Surgical Consideration is…